Momenta Pharmaceuticals, Inc. v. Amphastar Pharmaceuticals, Inc., 1:11-cv-11681-NMG. (2018)
Court: District Court, D. Massachusetts
Number: infdco20180220d89
Visitors: 20
Filed: Feb. 07, 2018
Latest Update: Feb. 07, 2018
Summary: DEFENDANTS' RENEWED MOTION FOR JUDGMENT AS A MATTER OF LAW ON UNPATENTABILITY AND INDEFINITENESS NATHANIEL M. GORTON , District Judge . Pursuant to Rule 50(b) of the Federal Rules of Civil Procedure, Defendants Amphastar Pharmaceuticals, Inc. and International Medication Systems, Ltd. (collectively, "Amphastar") hereby move for judgment as a matter of law on invalidity of U.S. Patent No. 7,575,886 ("the '886 patent"). Specifically, Amphastar seeks judgment of matter of law because the '886
Summary: DEFENDANTS' RENEWED MOTION FOR JUDGMENT AS A MATTER OF LAW ON UNPATENTABILITY AND INDEFINITENESS NATHANIEL M. GORTON , District Judge . Pursuant to Rule 50(b) of the Federal Rules of Civil Procedure, Defendants Amphastar Pharmaceuticals, Inc. and International Medication Systems, Ltd. (collectively, "Amphastar") hereby move for judgment as a matter of law on invalidity of U.S. Patent No. 7,575,886 ("the '886 patent"). Specifically, Amphastar seeks judgment of matter of law because the '886 ..
More
DEFENDANTS' RENEWED MOTION FOR JUDGMENT AS A MATTER OF LAW ON UNPATENTABILITY AND INDEFINITENESS
NATHANIEL M. GORTON, District Judge.
Pursuant to Rule 50(b) of the Federal Rules of Civil Procedure, Defendants Amphastar Pharmaceuticals, Inc. and International Medication Systems, Ltd. (collectively, "Amphastar") hereby move for judgment as a matter of law on invalidity of U.S. Patent No. 7,575,886 ("the '886 patent"). Specifically, Amphastar seeks judgment of matter of law because the '886 patent is: (1) directed to unpatentable subject matter under 35 U.S.C. § 101 and (2) indefinite under 35 U.S.C. § 112. In support of this Motion, Amphastar relies on its Memorandum of Law in Support of Defendants' Renewed Motion for Judgment as a Matter of Law on Unpatentability and Indefiniteness, filed herewith.
Motion denied.
Source: Leagle
